A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Amgen
Amgen
Janssen Research & Development, LLC
Bayer
Genmab
National Institutes of Health Clinical Center (CC)
Takeda
Dizal Pharmaceuticals
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Hoffmann-La Roche
Astellas Pharma Inc
Eli Lilly and Company
Mirati Therapeutics Inc.
Children's Oncology Group
Autolus Limited
Bayer